We have compared the capacity of dendritic cells ( 
Introduction
The activation of CD4 ϩ T cells is initiated by the recognition lead to selective expression of antigenic complexes either by antigen-specific B cells (3) or by DC (5). of peptide-class II MHC complexes on the surface of antigenpresenting cells (APC) like macrophages, dendritic cells (DC) DC represent a system of highly specialized APC present, in different stages of maturation, in the circulation as well as and B cells (1, 2) . Among the different APC populations capable of presenting peptide-class II MHC complexes, DC in lymphoid and non-lymphoid organs (6, 7) . Immature DC, such as Langerhans cells in the skin, are found in nonand B cells have been studied extensively, but their relative role in the presentation of protein antigen and CD4 ϩ T cell lymphoid tissues, where they exert a sentinel function. After antigen uptake, they migrate through the afferent lymph to Tpriming in vivo is still controversial. Using mice lacking B cells, presentation to CD4 ϩ T cells of antigenic complexes dependent areas of lymphoid organs where priming of naive T cells may occur (6, 8) . Based on in vitro data, it has been derived from processing of protein antigen administered in adjuvant was found in some studies to require B cells (3) , hypothesized that during this process they mature into potent APC by increasing their immunostimulatory properties while whereas in others B cells were found not critical and antigenic complexes were presumably presented by DC (4) . Similarly, losing their antigen capturing capacity (9,10). Thus, mature DC should have in vivo an impaired capacity to endocytose administration of soluble protein to normal mice was found to protein antigens but will present very efficiently peptides Bergisch Gladbach, Germany). Cells were incubated with B220-coated microbeads, and then separated into B220 ϩ derived from proteins which have been previously endocytosed at the site of inflammation.
and B220 -fractions on MiniMACS separation columns. To address this point, we have compared the relative Flow cytometry capacity of DC and B cells recruited in lymph nodes during the inflammatory response induced by adjuvant administration Cells were double stained by incubating them with optimal to present protein antigen administered in different forms. We concentrations of FITC-14.4.4S (anti-I-E) mAb, biotin-conjughave previously shown that immune lymph node cells (LNC) ated N418 (anti-CD11c) or 6B2 (anti-B220) mAb for 30 min from mice immunized with hen egg-white lysozyme (HEL) in at 4°C in PBS containing 5% FCS, 0.1% sodium azide and adjuvant display HEL peptide-MHC class II complexes able 1% normal rat serum to inhibit binding to FcR. 14.4.4S and to stimulate, in the absence of any further antigen addition, 6B2 mAb were purchased from PharMingen (San Diego, CA). specific T hybridoma cells (11, 12) .
N418 is an hamster mAb specific for mouse splenic DC In the present paper, HEL-specific T hybridoma cells were recognizing the p150/90 leukocyte integrin, likely the mouse used to read-out expression by DC and B cells of antigenic CD11c molecule (14,15), and was obtained from the ATCC complexes derived from processing of native HEL, either (HB-224; Rockville, MD). Biotinylated mAb were revealed given s.c. in adjuvant or in soluble form i.v. Phenotypic using phycoerythrin-streptavidin (Southern Biotechnology analysis of the stimulatory APC in immune lymph nodes Associates, Birmingham, AL). Analysis was performed on a confirms our previous study demonstrating that following s.c.
Becton Dickinson FACScan flow cytometer (Becton Dickinson, administration of HEL in adjuvant DC are the only APC Mountain View, CA). Data were collected on 5000-10,000 expressing detectable HEL peptide-class II complexes (13).
viable cells as determined by forward light scatter intensity Conversely, when HEL is administered in soluble form i.v. to and propidium iodide exclusion, and analyzed using Lysys II mice previously injected with adjuvant only, lymph node B software. cells are much more efficient than DC in the presentation of Assay for antigen-presenting activity HEL peptides. These results demonstrate that protein antigen injected in soluble form is presented best by B cells, whereas
The antigen-presenting activity of lymph node APC was the same protein is presented only by lymph node DC when assessed as previously described (11) IL-2 concentration was determined using a two-sites sandwich ELISA with paired mAb (JES6-1A12, JES6-5H4) purchased Enrichment of APC populations from PharMingen as described elsewhere (13). IL-2 was Immune LNC were depleted of T cells by cytotoxic elimination quantified from two to three titration points using standard with HO-13-4 anti-Thy-1.2 mAb (TIB 99) followed by rabbit curves generated by purified recombinant mouse IL-2 and complement (Low-Tox M; Cedarlane, London, Canada). Low results expressed as cytokine concentration in pg/ml. The and high buoyant density APC were prepared from T celldetection limit of the assay was 10 pg/ml. depleted LNC by centrifugation over a discontinuous Percoll (Pharmacia LKB, Uppsala, Sweden) gradient containing 55-Results 60% and 70% layers. Cells at the medium/55-60% and 60/ 70% interface were collected separately and referred to as Enrichment of DC and B cells low-and high-density APC respectively. B cells in the lowdensity population were further depleted by magnetic cell By a combination of Percoll gradient centrifugation and magnetic cell sorting, we separated lymph node APC into three sorting using the MiniMACS magnetic separation system following the manufacturer's instructions (Miltenyi Biotec, populations: small B cells, large B cells and DC-enriched cells ( Fig. 1 ). These populations were characterized by their determines preferential presentation of peptide-class II complexes by DC or B cells, we have analysed the capacity of expression of MHC class II, B220 and N418 molecules. The high-density population contains Ͼ95% B220 ϩ , class II ϩ resident lymph node APC to present antigenic complexes following i.v. administration of HEL in mice previously injected N418 -cells and is referred to as small B cells. Large B cells, obtained from the low-density population by positive selection with adjuvant. Injection of adjuvant recruits APC in the draining lymph nodes. Five days after administration of soluble HEL using B220 mAb-conjugated magnetic particles, are Ͼ95% B220 ϩ , class II ϩ , N418 ϩ . The negatively selected fraction, in the hind footpads popliteal lymph nodes harvested from nine mice yielded a total of 35 ϫ 10 6 cells which, after T cell depleted of B220 ϩ cells, is enriched in class II ϩ , N418 ϩ cells (50-70%) and is referred to as DC-enriched population.
depletion, were reduced to 1.6 ϫ 10 6 . Due to the very low number of cells recovered we could not proceed further with The mode of protein antigen administration determines cell enrichment. Cytofluorimetric analysis revealed that this preferential presentation of peptide-class II complexes by DC cell popluation contained 4% N418 ϩ cells, which represents or B cells a yield of 7 ϫ 10 3 cells/mouse. The average number of N418 ϩ cells obtained from lymph node cells after injection of adjuvant We have recently shown that following administration of HEL in adjuvant antigenic complexes are only detectable on lymph is 200 ϫ 10 3 mouse, corresponding to a 30-fold increase (data not shown). node DC, whereas B cells are devoid of antigen-presenting activity (13). In the present paper, we demonstrate that DC BALB/c mice were therefore immunized with an irrelevant antigen (OVA) in IFA to induce cell recruitment in draining isolated 3 and 6 days after injection of HEL in adjuvant present very efficiently the HEL epitope 108-116 bound to I-E d lymph nodes. Five days later, soluble HEL (100 nmoles/ mouse) was injected i.v. and popliteal lymph nodes collected molecules whereas its presentation decreases considerably by day 10 after priming. At all time points tested B cells, 3 h later. Amount and timing of soluble antigen injection were determined in pilot experiments (data not shown) and were either large or small, fail to present or present very inefficiently HEL108-116/E d complexes to T hybridoma cells (Fig. 2) . To found to be in agreement with previous results (3, 5, 18, 19) . APC populations were enriched as in Fig. 1 and assessed in determine whether the mode of protein antigen administration vitro for their antigen-presenting activity. Results in Fig. 3 using a fixed concentration of antigen (Fig. 4) , or by titration of antigen using a fixed concentration of APC (Fig. 5 ). In the demonstrate that HEL108-116/E d complexes derived from processing of HEL administered subcutaneously in IFA are latter case, 10 4 DC and 3 ϫ 10 5 small B cells/well were used to obtain a comparable T cell activation. Small B cells were only detectable on the DC-enriched population (Fig. 3A) . Conversely, small and large B cells are much more efficient chosen because they are more frequent than large B cells and more active in antigen presentation after administration than DC to activate T cell hybridomas when HEL is administered in soluble form i.v. (Fig. 3B) . To control for the intrinsic of soluble HEL (Fig. 3B) . The results indicate that, unlike B cells, DC recruited in draining lymph nodes by s.c. administracapacity of DC and B cells to activate class II-restricted T cells, we have analyzed presentation of naturally processed tion of adjuvant have a reduced ability to endocytose and process protein antigens, while they remain extremely efficient self-β 2 M peptides corresponding to the sequences 26-39 by I-A d molecules (17). All three APC populations constitutively in presenting antigenic peptides, likely as a consequence of their maturation in vivo. These data also show that for the express endogenously synthesized self-β 2 M peptide-A d complexes with the following hierarchy in presenting capacity: presentation of antigenic peptides DC are 10-to 30-fold more potent APC as compared with large and small lymph node B DC-enriched Ͼ large B cells Ͼ small B cells. The intrinsic capacity of these APC populations to present endogenously cells, respectively (Figs 4B and 5B). processed self-β 2 M peptides is comparable in both groups ( Fig. 3C and D) , whereas the capacity to present exogenous Discussion HEL is clearly different. These data demonstrate that the mode of protein antigen administration determines preferential Data in the present paper demonstrate that different modes of protein antigen administration lead to selective expression presentation of peptide-class II complexes by lymph node DC or B cells.
of antigenic complexes by different APC (Fig. 6 ). Following immunization with HEL in adjuvant, DC are the only lymph Lymph node DC present in vitro to class II-restricted T cells node APC population expressing detectable HEL peptideprotein antigen much less efficiently than synthetic peptides class II complexes, whereas B cells are much more efficient than DC in presenting antigenic complexes derived from The previous results could be explained by differences in the accessibility of circulating proteins to these APC populations, processing of circulating soluble HEL. To measure the capacity of resident lymph node APC (DC and B cells) to present or by their different potential in antigen uptake and processing in situ. To address this point we have compared the capacity peptides derived from processing of a circulating protein antigen, antigen has been injected shortly before lymph node of B cells and DC freshly isolated from immune lymph nodes to present HEL or HEL peptide 105-120 in vitro (Figs 4 and harvesting to minimize loading of APC before their entry into the lymph node. Under these conditions, lymph node B cells 5). No qualitative differences are observed for B cells, either small or large, in their capacity to present processed protein are far superior to DC in the presentation of HEL peptideclass II complexes to T hybridoma cells. These data correlate or synthetic peptide. Conversely, DC are very efficient in presenting the HEL peptide 105-120 but have an impaired with the impaired capacity of lymph node DC to present in vitro native protein antigen, as compared to synthetic capacity to present this epitope after processing of the native HEL protein. This is demonstrated either by titration of APC peptide, while no qualitative differences in the presentation . After 24 h of culture, IL-2 production was determined using a two-site sandwich ELISA.
due to the local secretion of proinflammatory cytokines such as tumor necrosis factor-α, which has been shown to downregulate the antigen-capturing and -processing capacity of human DC in vitro (21).
Since differences in antigen-presenting activity may also reflect differences in antigen uptake and processing capacity among the three APC populations tested, we analyzed in vitro the hierarchy in antigen-presenting activity to 1H11.3 T cells using synthetic peptide. As compared to large and small B cells, 10-to 30-fold less DC were needed to induce similar levels of IL-2 production by the T hybridoma cells. The number of antigenic complexes on DC required to activate T cells is much lower than for B cells (22) . Thus, the more efficient presentation of soluble antigen administered i.v. by B cells rather than DC is likely to reflect a much higher expression of antigenic complexes on B cells as compared to DC, indicating that the circulating protein has been preferentially uptaken and processed in vivo by lymph node B cells. antigen presentation by DC, thereby preventing the priming of potentially autoreactive T cells. On the other hand, once circulating antigen becomes available, lymph node B cells could further contribute to the clonal expansion of the antigenof protein and peptide are observed using B cells, in agreespecific T cells previously activated by DC (4, 23, 24) , although ment with previous results (20). Even if we cannot formally this issue is still controversial (3) . In this context, it is interesting exclude a possible inability of soluble antigen to access to note that soluble antigen administration usually results in lymph node DC in vivo, the in vitro data are consistent with T cell tolerance, mediated by antigen presentation by B cells, the interpretation that DC migrated to the lymph node have rather than DC (25 Constitutive presentation of dominant epitopes from endogenous
